Skip to content

An Iliopsoas Plane Block After Total Hip Arthroplasty

An Iliopsoas Plane Block for Pain Management After Total Hip Arthroplasty: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05212038
Enrollment
56
Registered
2022-01-27
Start date
2022-02-15
Completion date
2023-01-05
Last updated
2023-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Hip Arthroplasty

Brief summary

Nielsen et al. reported that when iliopsoas plane block was performed on healthy volunteers, the injection solution in Hip MRI was confined to the myofascial compartment, which was known to include all sensory branches of the femoral nerve that control the hip joint. The maximal muscle strength of knee extension did not decrease before and after Iliopsoas plane block in Volunteer. Since there is no clinical study conducted on patients after the volunteer study, the investigators intend to evaluate the analgesic and motor preserving effects of the iliopsoas plane block in a group of patients undergoing total hip arthroplasty.

Interventions

PROCEDUREiliopsoas plane block group

Ultrasound-guided iliopsoas plane block with 0.75% ropivacaine 10 ml and epinephrine 0.05 ml (1:200,000) 10 ml

PROCEDUREsham block group

Ultrasound-guided iliopsoas plane block with normal saline 10 ml

Sponsors

Gangnam Severance Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Double

Intervention model description

Parallel assignment

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients 19 years of age or older who are expected to undergo unilateral hip arthroplasty 2. ASA PS 1-3

Exclusion criteria

1. Revision total hip arthroplasty 2. Allergy to drugs used in the study 3. Patients with moderate or more hepatic impairment (AST/ALT is more than 2.5 times the upper limit of normal) 4. Estimated glomerular filtration rate \< 30 mL/min/1.73m2 5. Opioid dependence 6. Prolongation of PT and aPTT more than twice the upper limit of normal 7. Pre-existing neurological or anatomical disorders of the lower extremities 8. Serious psychiatric disorders

Design outcomes

Primary

MeasureTime frameDescription
Numeric rating scale pain score at restup to 48 hours after the surgeryPain intensity at rest will be evaluated by an 11-point numeric rating scale (NRS: 0 = no pain, 10 = worst imaginable pain) 1, 6, 24, and 48 hours after the surgery.

Secondary

MeasureTime frameDescription
Numeric rating scale pain score at movementup to 48 hours postoperativelyPain intensity during 45-degree passive flexion of the hip with the ipsilateral knee flexed naturally will be evaluated by an 11-point numeric rating scale (NRS: 0 = no pain, 10 = worst imaginable pain) 1, 6, 24, and 48 hours after the surgery.
Postoperative opioid consumptionpostoperative 24, 48hoursmorphine equivalent dose

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026